# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- SEC Filing
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company ...
-SEC Filing
Lake Street analyst Chad Messer initiates coverage on Oncolytics Biotech (NASDAQ:ONCY) with a Buy rating and announces Price...
Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(...